Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]

Description:

Recombinant monoclonal antibody to CD23. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the monkey B cell clone IDEC-152 (Lumiliximab, 6G5) .

Clone Name:

IDEC-152 (Lumiliximab, 6G5)

Published Application(s):

FC, Therapeutic, IP

Published Species Reactivity:

Human

5

Products based on this clone:

{{heading}}

Please Select

Ab02328-23.0 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]
Human
Rabbit IgG
Purified
In Stock

Ab02328-10.0 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]
Human
Human IgG1
Purified
In Stock

Ab02328-10.3 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]
Human
Human IgG1
Fc Silent™
Purified
Ships in 4-5 weeks

Ab02328-3.0 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]
Human
Mouse IgG2b
Purified
Ships in 4-5 weeks

Ab02328-3.3 Anti-CD23 [IDEC-152 (Lumiliximab, 6G5) ]
Human
Mouse IgG2b
Fc Silent™
Purified
In Stock

Loading...

UniProt Accession Number of Target Protein: P06734

Alternative Name(s) of Target: Gomiliximab; FCER2; BLAST-2; FcεRII; Fc-epsilon-RII; Low affinity immunoglobulin epsilon Fc receptor; C-type lectin domain family 4 member J; Immunoglobulin E-binding factor; Lymphocyte IgE receptor
Immunogen: The original chimeric antibody was generated from a monkey immunized with human CD23. Later on the chimeric version of the antibody was generated by cloning the variable regions of the antibody into human constant regions.

Specificity: This antibody binds the human CD23.

Application Notes: This antibody is also known as Gomiliximab. It binds CD23 or FCER2 which is a membrane protein and a "low affinity" receptor for IgE. It is also involved in IgE regulation and inflammation in allergic disorders, such as allergic rhinitis and allergic asthma. Phase I clinical trials in patients with allergic asthma revealed that IDEC-152 is safe and well tolerated (PMID: 13679816). This antibody is also reported to have antitumor activity against chronic lymphocytic leukemia (CLL) in clinical trials (Woodworth et al., 2004; Byrd et al., 2004). Phase 1 study of Lumiliximab in patients with relapsed or refractory chronic lymphocytic leukemia reported that it was well tolerated and had clinical activity in patient. Flow cytometric analyses of blood samples were conducted to assess changes in lymphocyte subsets and to study both CD23 expression and binding of lumiliximab during the treatment (PMID: 17671129). This antibody also causes apoptosis in vitro and in vivo in CLL cells and drug resistant lymphoma cells (Pathan et al., 2004; Zou et al., 2004). Lumiliximab was also found to inhibit allergen induced responses in antigen presenting cells and may be involved in modulating antigen presenting cells and reducing T H 2-type immune responses (PMID: 16210051). This antibody was also used in the detection of human CD23 in the B cell derived exosomes using immunoprecipitation (PMID: 20876574).

Antibody first published in: Rosenwasser et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol. (2003); 112(3):563-70. PMID:13679816
Note on publication: Describes the potential use of this antibody in the treatment of allergic asthma.